Lisa shares the story of her son Jace, who faced his diagnosis of a rare brain cancer with courage and compassion. His outlook continues to inspire the support Lisa now offers to other families navigating childhood cancer.

For people living with small cell lung cancer (SCLC), treatment decisions often come quickly and carry great importance. Resources like our Doctor Discussion Guide or Maintenance Therapy Fact sheet can help you be informed, active participants in your care journey. 

A medical emergency in a gym class started Megann’s life-changing journey with epilepsy, including a sudden diagnosis and intense treatment plan. Discover Megann’s inspiring story, detailing her challenges with treatment, loss of independence and how she empowers herself and other to live life to the fullest.

Extensive-stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy. Maintenance therapy may turn the period of stability after their first treatment into an opportunity to extend response and delay relapse.

We strive to put patient priorities first in our research, advancing our understanding of sleep conditions and the needs of those with narcolepsy and idiopathic hypersomnia.

People with sleep conditions, such as narcolepsy and idiopathic hypersomnia, have an increased prevalence of cardiovascular comorbidities compared to people without these sleep conditions. At Jazz, we aim to raise awareness of these connections through our research and partnerships with the goal of providing patients and healthcare providers with meaningful insights that can impact their lives.

Epilepsy is one of the most common neurological diseases in the world. While many treatments are available, there remains a significant unmet need among adult and pediatric patients who experience treatment-resistant seizures. Read more about how we are continuing to shine a light on the real-world burden associated with living with rare, treatment-resistant epileptic conditions.

For years, relapse after initial therapy has defined the outlook for people with extensive-stage small cell lung cancer (ES-SCLC). The FDA approval of a first-line maintenance combination regimen marks an important step forward, building on past progress and creating the possibility of longer-lasting benefit for patients and families.

Our teams at Jazz recognize the importance of collaborating with and learning from the sleep community. Our ongoing data generation is fueled by insights from people living with narcolepsy and idiopathic hypersomnia and expand our understanding of the realities of people living with these conditions.